76240-49-8

Usage

Uses

6-Bromophthalazine-1,4-diol is used as a research chemical in laboratory settings for various applications, primarily due to its unique chemical structure and properties. However, it does not have any significant commercial uses at this time. Its potential applications may include:
Used in Pharmaceutical Research:
6-Bromophthalazine-1,4-diol is used as a starting material or intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups may contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
6-Bromophthalazine-1,4-diol can be used as a building block in the synthesis of more complex organic compounds, such as dyes, pigments, or other specialty chemicals. Its bromine and hydroxyl groups can be further modified or functionalized to create new compounds with desired properties.
Used in Material Science:
6-Bromophthalazine-1,4-diol may have potential applications in the development of new materials with specific properties, such as conductivity, stability, or optical characteristics. Its aromatic and heterocyclic structure could contribute to the formation of novel materials with unique electronic or physical properties.

Upstream product

• 86-90-8 4-bromophthalic anhydride 

Downstream Products

• 1366408-06-1 8-bromo-13-(4-methoxyphenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-04-9 8-bromo-13-phenyl-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-05-0 8-bromo-13-(4-chlorophenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1366408-07-2 8-bromo-13-(3,4-dimethylphenyl)-3,4-dihydro-1H-indazolo[2,1-b]phthalazine-1,6,11(2H,13H)-trione 
• 1028338-57-9 7-bromo-4-chloro-2H-phthalazin-1-one 
• 1028338-59-1 6-bromo-4-chlorophthalazin-1(2H)-one 
• 240400-95-7 6-bromo-1,4-dichloro-phthalazine 
• 939052-90-1 6-bromo-2,3-bis(4-methoxybenzyl)-2,3-dihydrophthalazine-1,4-dione 

Relevant academic research and scientific papers

N -Chlorinative Ring Contraction of 1,4-Dimethoxyphthalazines via a Bicyclization/Ring-Opening Mechanism

An unprecedented N -chlorinative ring contraction of 1,2-diazines was discovered and investigated with an electrophilic chlorinating reagent, trichloroisocyanuric acid (TCICA). Through optimization and mechanistic analysis, the assisting role of n -Bu 4NCl as an exogenous nucleophile was identified, and the optimized reaction conditions were applied to a range of 1,4-dimethoxyphthalazine derivatives. Also, an improvement of overall efficiency was demonstrated by the use of a labile O -silyl group. A bicyclization/ring-opening mechanism, inspired by the Favorskii rearrangement, was proposed and supported by the DFT calculations. Furthermore, the efforts on scope expansion as well as the evaluation of other electrophilic promoters revealed that the newly developed ring contraction reactivity is a unique characteristic of 1,4-dimethoxyphthalazine scaffold and TCICA.

NEAR-INFRARED CHEMILUMINESCENCE EMITTER WITH AGGREGATION-INDUCED EMISSION PROPERTIES

Compounds including triphenylamine and luminol moieties exhibiting near-infrared chemiluminescence useful as reactive oxygen sensors, pharmaceutical compositions including the same, and methods of preparation and use thereof.

MTA-Cooperative PRMT5 Inhibitors

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

N-Chlorination-induced, oxidative ring contraction of 1,4-dimethoxyphthalazines

A rarely explored oxidative ring contraction of electron-rich 1,2-diazine is described. Upon treatment with an electrophilic chlorinating reagent (TCICA), 1,4-dimethoxyphthalazines undergo an N-chlorination-induced ring contraction that is accompanied by the loss of one nitrogen atom. The scope of this unusual reactivity was examined with a range of 1,4-dimethoxyphthalazine derivatives. In addition, a mechanism proceeding via a bicyclic species was proposed on the basis of an isolated reaction intermediate and DFT calculations.

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

Macrocyclic Compounds As Antiviral Agents

A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I):

PHTHALAZINE DERIVATIVES

The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Chemiluminescent energy-transfer cassettes based on fluorescein and nile red

The long and the short of it: Luminol chemiluminesces with a beautiful blue color; however, to be useful for biotechnological applications, the emission must be shifted to much longer wavelengths. Energy-transfer cassettes like that shown in the picture p

SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS

The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.